Starlight Posters

Aug, 2023

LP-184, a clinical stage acylfulvene-derived tumor site activated small molecule, inhibits adult and pediatric CNS tumor cell growth

Blood-brain barrier (BBB) permeable agents effective against recurrent, chemotherapy-resistant CNS tumors are urgently needed, particularly in Glioblastoma multiforme (GBM) and atypical teratoid/rhabdoid tumors (ATRT)

Button Text

Nov, 2022

Preclinical efficacy of LP-184, a tumor site activated synthetically lethal therapeutic, in glioblastoma

Temozolomide, the most effective standard-of-care chemotherapy for newly diagnosed glioblastoma, is ineffective in ~70% of patients due to MGMTdriven resistance and there is no effective chemotherapy for recurrent GBM

Button Text

Apr, 2022

LP-184, a tumor site activated small molecule synthetic lethal therapeutic, is effective in central nervous system cancers

Glioblastoma multiforme (GBM) and atypical teratoid/rhabdoid tumors (ATRT). These represent 2 extremely aggressive and lethal types of CNS malignancies sharing a median overall survival of 12- 18 months and 5-year survival rate of 5 to 30% in the US

Button Text

Nov, 2021

Utility of LP-184 as a CNS-bioavailable agent in glioblastoma, having been granted orphan drug designation

Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer with a 5-year survival rate of only 5% [1] with marginal improvements in this statistic over the last two decades.

Button Text

Apr, 2020

Use of expression-based machine learning-derived gene signatures to predict drug sensitivity profile and identify cancer indications for LP-184

A novel clinical agent, LP-184, is being developed by Lantern Pharma in conjunction with a dedicated machine learning-guided response signature, to allow optimal benefit and positioning of LP-184 through genomics-guided therapy.

Button Text